Medios

What Medios does

Medios AG is a Berlin-headquartered, Frankfurt-listed specialty pharmaceutical company that manufactures and distributes patient-individualized medicines, with FY2025 revenue exceeding €2.0 billion and operations spanning Germany, the Netherlands, Belgium, and Spain. The company operates two divisions: Specialty Pharma, which combines pharmaceutical wholesale, GMP-certified patient-specific drug compounding, and cold-chain distribution of high-value therapies (primarily oncology, immunology, and biologics) for partner pharmacies, clinics, and pharmaceutical manufacturers; and Advanced Therapies, a strategic initiative focused on biotechnological precision medicine. Revenue is generated principally through transaction-fee wholesale distribution and GMP compounding services, supplemented by a digital service infrastructure that provides workflow and traceability tools to pharmacy and clinic partners.

The business model is B2B enterprise field sales targeting specialty pharmacies, clinics, pharmaceutical manufacturers, and clinical study sponsors under Germany's regulated reimbursement framework. The platform is vertically integrated across procurement, quality assurance, GMP compounding, cold-chain logistics, and digital workflow tools, serving as critical last-mile infrastructure for personalized medicine in Germany. Go-to-market is relationship-driven, with pricing obtained via direct sales engagement rather than published rates, and customer base distributed across many partner pharmacies and institutions.

Medios has executed a deliberate European platform strategy: the June 2024 close of the Ceban Pharmaceuticals B.V. acquisition (€235.3M cash plus 1.7M shares) added compounding operations in the Netherlands, Belgium, and Spain; founder Manfred Schneider sold a 14.9% stake to Luxempart S.A. to support internationalization; and a January 2026 exclusive distribution partnership with Bedrocan extended reach into medical cannabis with stated plans to expand into Austria, Belgium, Italy, and Spain. Defensive actions have accompanied expansion: the Aschaffenburg production site (~10% of German volume, 32 staff) was closed in mid-2026 to consolidate patient-individual manufacturing amid regulatory and pricing pressure, and FY2026 adjusted EBITDA guidance was cut to €88-92M from €94-102M while revenue guidance was raised to €2.10-2.16B, reflecting a margin-protection posture alongside top-line growth.

Name

Medios

Legal name

Medios AG

Website

https://medios.ag

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Medios AG is a Berlin-based specialty pharmaceutical company that manufactures and distributes patient-individualized medications, operates GMP-certified compounding facilities, and serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

akta.pro secondary industries

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Specialty pharmaceuticals
• Patient-specific medicines
• Pharmaceutical compounding services
• Individualized oncology therapies
• Cold-chain drug distribution

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical Supply (Specialty Pharma Trading): Wholesale distribution of high-value specialty pharmaceuticals to partner pharmacies and clinics across Germany. This includes procurement, quality assurance, and distribution of specialty drugs for complex diseases.
2. Drug Compounding Services: GMP-certified patient-specific compounding and manufacturing services for individualized medications, primarily serving oncology, immunology, and biologic treatment markets.
3. Digital Service Infrastructure: Digital service infrastructure for pharmacy and clinic workflows, providing integration and operational support services.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Medios AG manufactures and supplies patient-specific medicinal products through pharmaceutical wholesale, GMP-certified drug compounding for individualized therapies, and cold-chain distribution. The company serves specialty pharmacies, clinics, and pharmaceutical manufacturers across Germany and Europe with a focus on oncology, immunology, and biologic treatments. Operating as a vertically integrated specialty pharma platform, Medios combines procurement, quality assurance, GMP-certified manufacturing, and digital traceability to support personalized medicine delivery.

Product overview

Medios AG operates as a vertically integrated specialty pharma platform combining pharmaceutical wholesale, GMP-certified patient-specific drug compounding, and digital distribution services for high-cost therapies. The platform spans two core divisions: Specialty Pharma (drug supply, patient-individual compounding, and distribution for oncology and autoimmune disorders) and Advanced Therapies (biotechnology precision medicine). The company serves manufacturers, specialty pharmacies, clinics, and pharmaceutical companies across Germany and Europe, supporting its partner-first integration model with cold-chain logistics and digital service infrastructure.

Differentiator

Problem solved

Functional benefit

Products and services

• Specialty Pharma Pharmaceutical wholesale, drug procurement, quality assurance, and distribution of high-value specialty medications for specialty pharmacies, clinics, and pharmaceutical companies. Includes cold-chain logistics and patient-individual manufacturing operations.
• Advanced Therapies Cutting-edge biotechnological precision medicine and advanced therapy products representing the company's strategic initiative in biotechnology-based treatments.
• GMP-Certified Compounding Services

Quantifiable outcome

• Record H1 2026 revenue of €1,075 million, up from €991.7 million in H1 2025
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• BedrocancoreStrategic or Co-development Partner · 20 January 2026Exclusive distribution partnership for medicinal cannabis products. Medios appointed as exclusive distribution partner for Bedrocan's products in Germany, with plans to expand to Austria, Belgium, Italy, and Spain. Medios distributes cannabis produced at Bedrocan's EU-GMP certified facility in Denmark, leveraging existing Cannaflos network for seamless transition. Partnership streamlines procurement for German pharmacists who previously navigated fragmented distribution markets.
• Ceban Pharmaceuticals B.V.coreStrategic or Co-development Partner · 18 March 2024Acquisition of Ceban Pharmaceuticals B.V., a leading Dutch pharmaceutical compounding platform with operations in Belgium and Spain. Deal involved €235.3 million cash component and 1.7 million Medios shares. Part of strategy to build a European Specialty Pharma platform, expected to significantly boost revenue and profitability by 2024 and 2025. Acquisition completed in June 2024.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aenova Group: Aenova is one of Europe's largest CDMOs offering solid, semi-solid, liquid, sterile, and biological contract manufacturing services from multiple European sites. Comparable to Medios's GMP-certified compounding and manufacturing operations for high-value drugs, though more diversified across dosage forms.
• NextPharma: NextPharma is a European specialty CDMO focused on sterile liquids, semi-solids, and patient-specific manufacturing across multiple European sites. Directly comparable to Medios's GMP-certified patient-specific compounding and sterile manufacturing capabilities for specialty drugs.
• Stada Arzneimittel AG: Stada is a major German specialty pharmaceutical company with operations in generics, specialty pharma, and consumer health, including compounding and distribution. Comparable to Medios as a Germany-based specialty pharma platform with focus on niche/individualized medicines.
• Dermapharm Holding SE: Dermapharm is a German specialty pharmaceutical manufacturer focused on niche/rare disease products and parallel imports. Comparable to Medios's specialty pharma strategy targeting smaller patient populations with high-value therapies, though with more emphasis on dermatology and rare disease.
• Sanacorp eG: Sanacorp is Germany's largest pharmaceutical wholesale cooperative serving pharmacies with a broad portfolio including specialty drugs. Directly comparable to Medios's pharmaceutical wholesale and distribution activities to German pharmacies, though without the compounding specialization.
• PharmaZell (SEQENS): PharmaZell (now part of SEQENS) is a European specialty API and CDMO with focus on niche molecules and complex manufacturing. Comparable to Medios's specialty pharma positioning, particularly in patient-specific and complex therapies, though concentrated on APIs and complex small molecules.
• Hameln Pharma (Piramal Pharma Solutions): Hameln Pharma (now part of Piramal) is a German specialty CDMO specializing in sterile injectables, ampoules, and complex injectable formulations. Directly comparable to Medios's GMP-certified sterile compounding capabilities, particularly for oncology and individualized injectable therapies.

Broad incumbents

• Recipharm AB: Recipharm is a major European CDMO offering a broad range of pharmaceutical contract manufacturing services across multiple dosage forms and technologies. Comparable to Medios's GMP manufacturing footprint, though much larger and broader in scope (lacks the specialty pharmacy distribution angle).
• Alliance Healthcare (Walgreens Boots Alliance): Alliance Healthcare is a major European pharmaceutical wholesaler and distributor serving pharmacies across multiple countries. Comparable to Medios's wholesale distribution business, but at much greater scale and without the GMP compounding vertical.

Regional players

• Polpharma: Polpharma is the largest Polish pharmaceutical manufacturer and a leading Central/Eastern European specialty pharma player. Comparable to Medios's specialty pharma manufacturing and distribution model, though primarily serving Polish and CEE markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@medios-group?si=MVIV2I0K_Q-FRtJb
• LinkedInlinkedin.com/company/mediosgroup

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medios